Study Title: Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
 

• Status: Terminated Early

• Participating Sites:
  • University of Michigan Rogel Cancer Center
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
  • University of Wisconsin Carbone Cancer Center
• Learn more:
  • clinicaltrials.gov: NCT03927105
  • Big Ten CRC News Release

Study Contact: studies@hoosiercancer.org; (317) 921-2050.